SOURCE: OmniComm Systems, Inc.

OmniComm Systems, Inc.

December 14, 2010 09:00 ET

OmniComm Systems' TrialOne® Suite Chosen by Top 5 Major Pharmaceutical Company

TrialOne Chosen to Automate Clinical Research Within Early-Phase Clinic

FORT LAUDERDALE, FL--(Marketwire - December 14, 2010) - OmniComm Systems, Inc. (OTCBB: OMCM), one of the fastest growing companies in the EDC marketplace, today announced that its TrialOne suite of applications has been chosen by a Major Pharmaceutical company to automate their clinical trial operations and processes within their early-phase (phase I, BA-BE/PK-PD and Phase IIa) clinic.

TrialOne is a web-based, mobile, source data capture solution designed specifically for early-phase clinical trials to facilitate recruitment, appointment scheduling, study building and design, screening, source data capture, sample tracking and reporting. TrialOne offers time-based data entry and integration with bar-code scanners & printers and biomedical monitoring devices to automate data collection and processing. The flexible and configurable workflow streamlines operational and data management and raises protocol compliance while enhancing data quality.

"The selection of TrialOne by this global pharmaceutical company validates the breadth of functionality, flexibility, and usability of this product suite," said Stephen Johnson, President and COO of OmniComm. "As the complexity and number of early-phase trials continues to increase, the need for automation and specialized technology has grown significantly, especially among large Pharma and CROs. There aren't a lot of quality solutions in this space, especially solutions that are integrated and web-based. Traditional EDC solutions lack the functionality necessary to handle early-phase trials. Most companies that conduct early-phase trials have had to settle with paper and homegrown solutions to accommodate their unique needs. TrialOne is the first fully comprehensive, web-based solution that is written specifically for those needs."

About OmniComm

OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's pricing model is easily understood and allows companies ranging from small, to large, to maximize their clinical research investments. OmniComm Systems, Inc has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey and the United Kingdom, as well as sales offices throughout the U.S. and Europe.

Safe Harbor Disclaimer
Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact Information